Covid-19 Research

Case Report

OCLC Number/Unique Identifier: 9124866518

Pneumocystis Jirovecii Pneumonia as a Sequela of COVID-19

Medicine Group    Start Submission

Syed Muhammad Zubair, Hamid Hussain Muhammad Zaid and Shahzad Talha*

Volume2-Issue6
Dates: Received: 2021-05-12 | Accepted: 2021-05-31 | Published: 2021-06-01
Pages: 425-428

Abstract

A 71 years old male came to the hospital with the complaint of cough and fever since 7 days. He was diagnosed with severe COVID pneumonia and was managed with steroids and tocilizumab. He was discharged on steroids and came after 20 days with complaints of worsening shortness of breath and hypoxia. Bronchoscopy and bronchoalveolar lavage was done which showed positive PCR for Pneumocystis Jirovecii Pneumonia (PCP). Patient was started on co-trimoxazole and steroids after which he showed remarkable improvement. This is one of the rare cases in which patient developed PCP as a sequelae of COVID-19.

FullText HTML FullText PDF DOI: 10.37871/jbres1253


Certificate of Publication




Copyright

© 2021 Zubair SM, et al. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Zubair SM, Muhammad Zaid HH, Talha S. Pneumocystis Jirovecii Pneumonia as a Sequela of COVID-19 Pneumocystis Jiroveciii Pneumonia as a Sequela of COVID-19. J Biomed Res Environ Sci. 2021 June 01; 2(6): 425-428. doi: 10.37871/jbres1253, Article ID: jbres1253


Subject area(s)

References


  1. Candan SA, Elibol N, Abdullahi A. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19. Physiother Theory Pract. 2020 Jun;36(6):663-668. doi: 10.1080/09593985.2020.1766181. Epub 2020 May 18. PMID: 32419564.
  2. Lahiri D, Ardila A. COVID-19 Pandemic: A Neurological Perspective. Cureus. 2020 Apr 29;12(4):e7889. doi: 10.7759/cureus.7889. PMID: 32489743; PMCID: PMC7255551.
  3. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020 Aug;63(8):766-770. doi: 10.1111/myc.13135. Epub 2020 Jul 18. PMID: 32585069; PMCID: PMC7361517.
  4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
  5. Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan XG. Bacterial and fungal infections in COVID-19 patients: A matter of concern. Infect Control Hosp Epidemiol. 2020 Sep;41(9):1124-1125. doi: 10.1017/ice.2020.156. Epub 2020 Apr 22. PMID: 32317036; PMCID: PMC7184139.
  6. Rijnders BJA, Schauwvlieghe AFAD, Wauters J. Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination? Clin Infect Dis. 2020 Oct 23;71(7):1764-1767. doi: 10.1093/cid/ciaa010. PMID: 31905234; PMCID: PMC7583400.
  7. Bruno G, Fabrizio C, Buccoliero GB. COVID-19-associated pulmonary aspergillosis: adding insult to injury. Lancet Microbe. 2020 Jul;1(3):e106. doi: 10.1016/S2666-5247(20)30063-X. Epub 2020 Jul 3. PMID: 32835340; PMCID: PMC7333985.
  8. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020 Jun;8(6):e48-e49. doi: 10.1016/S2213-2600(20)30237-X. Epub 2020 May 20. PMID: 32445626; PMCID: PMC7239617.
  9. Menon AA, Berg DD, Brea EJ, Deutsch AJ, Kidia KK, Thurber EG, Polsky SB, Yeh T, Duskin JA, Holliday AM, Gay EB, Fredenburgh LE. A Case of COVID-19 and Pneumocystis jirovecii Coinfection. Am J Respir Crit Care Med. 2020 Jul 1;202(1):136-138. doi: 10.1164/rccm.202003-0766LE. PMID: 32412848; PMCID: PMC7328312.
  10. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009 Jul 15;88(1):135-41. doi: 10.1097/TP.0b013e3181aad256. PMID: 19584693.
  11. Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population. Ann Pharmacother. 2016 Aug;50(8):673-9. doi: 10.1177/1060028016650107. Epub 2016 May 30. PMID: 27242349.
  12. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbì L, Girardis M, Tedeschi S, Giannella M, Bartoletti M, Pascale R, Dolci G, Brugioni L, Pietrangelo A, Cossarizza A, Pea F, Clini E, Salvarani C, Massari M, Viale PL, Mussini C. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24. Erratum in: Lancet Rheumatol. 2020 Oct;2(10):e591. PMID: 32835257; PMCID: PMC7314456.
  13. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15. PMID: 32253759; PMCID: PMC7262125.
  14. Zain Mushtaq M, Bin Zafar Mahmood S, Jamil B, Aziz A, Ali SA. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience. Int Immunopharmacol. 2020 Nov;88:106926. doi: 10.1016/j.intimp.2020.106926. Epub 2020 Aug 28. PMID: 32889236; PMCID: PMC7455148.
  15. Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7. Erratum in: Drugs. 2017 Dec 19;: PMID: 29094311; PMCID: PMC5736769.
  16. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, Goto H. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 2011;50(4):305-13. doi: 10.2169/internalmedicine.50.4508. Epub 2011 Feb 15. PMID: 21325762.
  17. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1. PMID: 21884601; PMCID: PMC3308069.


Comments


Swift, Reliable, and studious. We aim to cherish the world by publishing precise knowledge.

  • Brown University Library
  • University of Glasgow Library
  • University of Pennsylvania, Penn Library
  • University of Amsterdam Library
  • The University of British Columbia Library
  • UC Berkeley’s Library
  • MIT Libraries
  • Kings College London University
  • University of Texas Libraries
  • UNSW Sidney Library
  • The University of Hong Kong Libraries
  • UC Santa Barbara Library
  • University of Toronto Libraries
  • University of Oxford Library
  • Australian National University
  • ScienceOpen
  • UIC Library
  • KAUST University Library
  • Cardiff University Library
  • Ball State University Library
  • Duke University Library
  • Rutgers University Library
  • Air University Library
  • UNT University of North Texas
  • Washington Research Library Consortium
  • Penn State University Library
  • Georgetown Library
  • Princeton University Library
  • Science Gate
  • Internet Archive
  • WashingTon State University Library
  • Dimensions
  • Zenodo
  • OpenAire
  • Index Copernicus International
  • icmje
  •  International Scientific Indexing (ISI)
  • Sherpa Romeo
  • ResearchGate
  • Universidad De Lima
  • WorldCat
  • JCU Discovery
  • McGill
  • National University of Singepore Libraries
  • SearchIT
  • Scilit
  • SemantiScholar
  • Base Search
  • VU
  • KB
  • Publons
  • oaji
  • Harvard University
  • sjsu-library
  • UWLSearch
  • Florida Institute of Technology
  • CrossRef
  • LUBsearch
  • Universitat de Paris
  • Technical University of Denmark
  • ResearchBIB
  • Google Scholar
  • Microsoft Academic Search

 

 

WhatsApp
+1(315) 654-9165